These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 15599089)

  • 1. The R(-)-enantiomer of efonidipine blocks T-type but not L-type calcium current in guinea pig ventricular myocardium.
    Tanaka H; Komikado C; Shimada H; Takeda K; Namekata I; Kawanishi T; Shigenobu K
    J Pharmacol Sci; 2004 Dec; 96(4):499-501. PubMed ID: 15599089
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Frequency-dependent blockade of T-type Ca2+ current by efonidipine in cardiomyocytes.
    Masumiya H; Kase J; Tanaka Y; Tanaka H; Shigenobu K
    Life Sci; 2000 Dec; 68(3):345-51. PubMed ID: 11191650
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Species difference in the contribution of T-type calcium current to cardiac pacemaking as revealed by r(-)-efonidipine.
    Tanaka H; Komikado C; Namekata I; Nakamura H; Suzuki M; Tsuneoka Y; Shigenobu K; Takahara A
    J Pharmacol Sci; 2008 May; 107(1):99-102. PubMed ID: 18460822
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of myocardial L- and T-type Ca2+ currents by efonidipine: possible mechanism for its chronotropic effect.
    Masumiya H; Shijuku T; Tanaka H; Shigenobu K
    Eur J Pharmacol; 1998 May; 349(2-3):351-7. PubMed ID: 9671117
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A selective T-type Ca2+ channel blocker R(-) efonidipine.
    Shin MC; Kim CJ; Min BI; Ogawa S; Tanaka E; Akaike N
    Naunyn Schmiedebergs Arch Pharmacol; 2008 Jun; 377(4-6):411-21. PubMed ID: 18278483
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of R(-)-isomer of efonidipine as a selective blocker of T-type Ca2+ channels.
    Furukawa T; Miura R; Honda M; Kamiya N; Mori Y; Takeshita S; Isshiki T; Nukada T
    Br J Pharmacol; 2004 Dec; 143(8):1050-7. PubMed ID: 15545287
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efonidipine hydrochloride: a dual blocker of L- and T-type ca(2+) channels.
    Tanaka H; Shigenobu K
    Cardiovasc Drug Rev; 2002; 20(1):81-92. PubMed ID: 12070536
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibitory effect of efonidipine on aldosterone synthesis and secretion in human adrenocarcinoma (H295R) cells.
    Imagawa K; Okayama S; Takaoka M; Kawata H; Naya N; Nakajima T; Horii M; Uemura S; Saito Y
    J Cardiovasc Pharmacol; 2006 Jan; 47(1):133-8. PubMed ID: 16424797
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pathophysiological significance of T-type Ca2+ channels: T-type Ca2+ channels and drug development.
    Tanaka H; Shigenobu K
    J Pharmacol Sci; 2005 Nov; 99(3):214-20. PubMed ID: 16293935
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Actions of mibefradil, efonidipine and nifedipine block of recombinant T- and L-type Ca channels with distinct inhibitory mechanisms.
    Lee TS; Kaku T; Takebayashi S; Uchino T; Miyamoto S; Hadama T; Perez-Reyes E; Ono K
    Pharmacology; 2006; 78(1):11-20. PubMed ID: 16899990
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Beneficial effects of the dual L- and T-type Ca2+ channel blocker efonidipine on cardiomyopathic hamsters.
    Suzuki S; Ohkusa T; Ono K; Sato T; Yoshida MA; Yano M; Takebayashi S; Matsuzaki M
    Circ J; 2007 Dec; 71(12):1970-6. PubMed ID: 18037756
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protective effects of efonidipine, a T- and L-type calcium channel blocker, on renal function and arterial stiffness in type 2 diabetic patients with hypertension and nephropathy.
    Sasaki H; Saiki A; Endo K; Ban N; Yamaguchi T; Kawana H; Nagayama D; Ohhira M; Oyama T; Miyashita Y; Shirai K
    J Atheroscler Thromb; 2009 Oct; 16(5):568-75. PubMed ID: 19749494
    [TBL] [Abstract][Full Text] [Related]  

  • 13. T-type Ca2+ channel blockade prevents sudden death in mice with heart failure.
    Kinoshita H; Kuwahara K; Takano M; Arai Y; Kuwabara Y; Yasuno S; Nakagawa Y; Nakanishi M; Harada M; Fujiwara M; Murakami M; Ueshima K; Nakao K
    Circulation; 2009 Sep; 120(9):743-52. PubMed ID: 19687356
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of newer calcium channel antagonists: therapeutic potential of efonidipine in preventing electrical remodelling during atrial fibrillation.
    Ohashi N; Mitamura H; Ogawa S
    Drugs; 2009; 69(1):21-30. PubMed ID: 19192934
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Divergent renal vasodilator action of L- and T-type calcium antagonists in vivo.
    Honda M; Hayashi K; Matsuda H; Kubota E; Tokuyama H; Okubo K; Takamatsu I; Ozawa Y; Saruta T
    J Hypertens; 2001 Nov; 19(11):2031-7. PubMed ID: 11677369
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of efonidipine on TGF-β1-induced cardiac fibrosis through Smad2-dependent pathway in rat cardiac fibroblasts.
    Lei B; Hitomi H; Mori T; Nagai Y; Deguchi K; Mori H; Masaki T; Nakano D; Kobori H; Kitaura Y; Nishiyama A
    J Pharmacol Sci; 2011; 117(2):98-105. PubMed ID: 21897055
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of efonidipine, an L- and T-type calcium channel blocker, on the renin-angiotensin-aldosterone system in chronic hemodialysis patients.
    Nakano N; Ishimitsu T; Takahashi T; Inada H; Okamura A; Ohba S; Matsuoka H
    Int Heart J; 2010 May; 51(3):188-92. PubMed ID: 20558909
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Blocking T-type Ca2+ channels with efonidipine decreased plasma aldosterone concentration in healthy volunteers.
    Okayama S; Imagawa K; Naya N; Iwama H; Somekawa S; Kawata H; Horii M; Nakajima T; Uemura S; Saito Y
    Hypertens Res; 2006 Jul; 29(7):493-7. PubMed ID: 17044661
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular pharmacology of human Cav3.2 T-type Ca2+ channels: block by antihypertensives, antiarrhythmics, and their analogs.
    Perez-Reyes E; Van Deusen AL; Vitko I
    J Pharmacol Exp Ther; 2009 Feb; 328(2):621-7. PubMed ID: 18974361
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efonidipine reduces proteinuria and plasma aldosterone in patients with chronic glomerulonephritis.
    Ishimitsu T; Kameda T; Akashiba A; Takahashi T; Ohta S; Yoshii M; Minami J; Ono H; Numabe A; Matsuoka H
    Hypertens Res; 2007 Jul; 30(7):621-6. PubMed ID: 17785930
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.